Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease.

Alimentary pharmacology & therapeutics - 1 Jun 2020

Bangma Amber, Voskuil Michiel D, Uniken Venema Werna T C, Brugge Harm, Hu Shixian, Lanting Pauline, Franke Lude, Dijkstra Gerard, Festen Eleonora A M, Weersma Rinse K

Abstract excerpt

BACKGROUND: High inter-individual variability in therapeutic response to drugs used in the management of Inflammatory Bowel Disease (IBD) leads to high morbidity and high costs. Genetic variants predictive of thiopurine-induced myelosuppression, thiopurine-induced pancreatitis and immunogenicity of Tumour Necrosis Factor alpha (TNFα) antagonists have been identified, but uptake of pre-treatment pharmacogenetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Immunosuppressive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inflammatory Bowel Diseases

Share to Pharmacogenomic Testing

Share to Pharmacogenomic Variants

Share to Predictive Value of Tests

Share to Reproducibility of Results

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 32363635
DOI: 10.1111/apt.15762
PMCID: PMC7318341

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease.PMID 32363635Read ↗

Treatment of Chronic Inflammatory Diseases – The Potential of PharmacogeneticsSemantic proximity Read ↗

Pharmacogenetics of Inflammatory Bowel DiseaseSemantic proximity Read ↗

Pharmacogenetics of inflammatory bowel disease.Semantic proximity Read ↗

Combining explainable machine learning, demographic and multi-omic data to identify precision medicine strategies for inflammatory bowel diseaseSemantic proximity Read ↗

Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients.Semantic proximity Read ↗

The genetics of IBD : from susceptibility to drug response and patient outcomeSemantic proximity Read ↗

Pharmacogenetic Risk Factors for Thiopurine-Induced Leukopenia in Patients with Inflammatory Bowel Disease.Semantic proximity Read ↗

Landscape of TPMT and NUDT15 Pharmacogenetic Variation in a Cohort of Canadian Pediatric Inflammatory Bowel Disease Patients.Semantic proximity Read ↗

Pharmacogenetics of treatments for inflammatory bowel diseaseSemantic proximity Read ↗

Development of a Machine Learning Model to Predict Non-Durable Response to Anti-TNF Therapy in Crohn’s Disease Using Transcriptome Imputed from GenotypesSemantic proximity Read ↗

Exploring inflammatory bowel disease therapy targets through druggability genes: a Mendelian randomization study.Semantic proximity Read ↗

Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.